tbuckley/cabot-search huggingface dataset:
Clusterin production in the obstructed rabbit kidney
Authors: P N Schlegel, G J Matthews, Z Cichon, W K Aulitzky, C Y Cheng, C L Chen, L Saso, M Goldstein, O A Jänne, C W Bardin
Journal: Journal of the American Society of Nephrology (1992)

Clusterin, a protein associated with cell death, has been suggested as a marker of renal injury. Correlation of clusterin gene expression with changes in renal function and quantitative measurement of clusterin protein levels after ureteral obstruction have not been previously reported. With unilateral ureteral obstruction in rabbits as the experimental model, the time course of alterations in renal function, clusterin mRNA accumulation, and concentrations of clusterin protein in serum, urine, and renal tissue were investigated. RBF, GFR, and renal concentrating ability (percent sodium reabsorption and urine osmolarity) all decreased (P < 0.05) in the obstructed kidney from control values within 1 day of ureteral obstruction. Clusterin mRNA levels started to rise in the ipsilateral kidney within 12 h of ureteral obstruction and increased up to 10-fold above control levels after 3 days of obstruction. Hybridization histochemistry showed that clusterin mRNA was initially detectable in collecting ducts and distal tubules within 12 h of ureteral obstruction. After 7 days of obstruction, increased accumulation of clusterin mRNA was also detectable in proximal tubular epithelial cells. Clusterin gene expression remained elevated in collecting ducts after 60 days of obstruction. Clusterin expression in the contralateral kidney was increased twofold over control values after 12 h of obstruction. No increase in clusterin mRNA accumulation was detectable after 24 h in the contralateral kidney. Total clusterin protein in the obstructed kidney increased from 0.59 +/- 0.66 (mean +/- 1 SD) to 2.5 +/- 1.3 micrograms after 7 days of ureteral obstruction (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Characterization and assessment of nanoencapsulated sanguinarine chloride as a potential treatment for melanoma
Authors: Jamie Rosen, Angelo Landriscina, Brandon L Adler, Aimee Krauz, Jessica Doerner, Mahantesh Navati, Tagai Musaev, Claudia Gravekamp, Joshua Nosanchuk, Adam J Friedman
Journal: Journal of the American Academy of Dermatology (2015)
Management of Opioid Analgesic Overdose
Authors: Edoardo Picetti, Ilaria Rossi, M Luisa Caspani
Journal: New England Journal of Medicine (2012)

Opioid analgesic overdose is a preventable and potentially lethal condition that results from prescribing practices, inadequate understanding on the patient's part of the risks of medication misuse, errors in drug administration, and pharmaceutical abuse. 1,2Three features are key to an understanding of opioid analgesic toxicity.First, opioid analgesic overdose can have life-threatening toxic effects in multiple organ systems.Second, normal pharmacokinetic properties are often disrupted during an overdose and can prolong intoxication dramatically. 3Third, the duration of action varies among opioid formulations, and failure to recognize such variations can lead to inappropriate treatment decisions, sometimes with lethal results. 2,4
lofetamine HCI I-123 (lodoamphetamine) Brain SPECT Atlas
Authors: MARK FALLS, CHAN H. PARK, MARK MADSEN
Journal: Clinical Nuclear Medicine (1985)

SPECT brain imaging using lofetamine HCI I-123 (IMP) has a great potential in the evaluation of various neurologic disorders. Transverse, coronal, and sagittal sectional IMP images obtained using a single head rotating gamma camera system are correlated with corresponding normal brain slices in this atlas.
HG-88NOVEL ANTIBODIES TO STUDY HISTONE H3.3 MUTATIONS IN DIPG AND pHGG
Authors: Farhana Haque, Aikaterini Bountali, Ruman Rahman, Angel Montero Carcaboso, Pascale Varlet, Jacques Grill, Chris Jones, Robert Layfield, Richard Grundy
Journal: Neuro-Oncology (2016)
Evaluation of a New Sulfonamide Sulfamethoxazole
Authors: L SMITH
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of Androgens on Shionogi Carcinoma 115 Cells In Vitro 2
Authors: D. J. A. Sutherland, E. C. Robins,, J. W. Meakin
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Effects of Androgens on Shionogi Carcinoma 115 Cells In Vitro Get access D. J. A. Sutherland, D. J. A. Sutherland Search for other works by this author on: Oxford Academic PubMed Google Scholar E. C. Robins,, E. C. Robins, Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Meakin J. W. Meakin Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 1, January 1974, Pages 37–48, https://doi.org/10.1093/jnci/52.1.37 Published: 01 January 1974 Article history Received: 09 March 1973 Revision received: 23 August 1973 Accepted: 10 September 1973 Published: 01 January 1974
A comparison of biofeedback-mediated relaxation and group therapy in the treatment of chronic anxiety
Authors: R E Townsend, J F House, D Addario
Journal: American Journal of Psychiatry (1975)

The authors compared treatment of chronic anxiety with biofeedback-mediated electromyographic (EMG) relaxation to treatment with group psychotherapy in a control group. Feedback patients were given two weeks of EMG relaxation training followed by two weeks of self-practice. Significant decreases were found in the feedback group in electromyogram levels, mood distrubance, trait anxiety, and (to a lesser extent) state anxiety; no such decreases occurred in the control group. The authors suggest that EMG feedback can be an important adjunct therapy for chronic anxiety.
Clinical Heterogeneity Of Autoimmune Hemolytic Anemia: A 35-Years Retrospective Study Of 157 Patients
Authors: Wilma Barcellini, Bruno Fattizzo, Tommaso Radice, Anna Zaninoni, Nicoletta Revelli, Maria Antonietta Villa, Carla Boschetti, Agostino Cortelezzi, Alberto Zanella
Journal: Blood (2013)
HG-37SECOND RE-IRRADIATION FOR DIPG PROGRESSION, RE-CONSIDERING “OLD STRATEGIES” WITH NEW APPROACHES
Authors: Andres Morales La Madrid, Vicente Santa-Maria, Ofelia Cruz Martinez, Alvaro Lassaletta, Normand Laperriere, Salvador Villa, Eric Bouffet
Journal: Neuro-Oncology (2016)

Diffuse intrinsic pontine glioma (DIPG) is an aggressive infiltrative glioma for which no curative therapy is available. Radiation therapy (RT) is the only potentially effective intervention in delaying tumor progression, but only transiently. At progression, re-irradiation is gaining popularity as an effective palliative therapy. However, at second progression, exclusive symptomatic treatment is usually offered. Here we report two patients with DIPG at second progression who were treated with a second re-irradiation course with good response. Importantly, treatment was well tolerated with no irradiation associated acute toxicity identified.
Some guidelines for the training of foreign medical graduates: results of a special project
Authors: J F Mcdermott, T W Maretzki
Journal: American Journal of Psychiatry (1975)

Since over one-third of the psychiatric residency positions in the United states are filled by foreign medical graduates, there is a need to identify and correct both the emotional and cognitive problems of these medical trainees. To meet this need the authors describe the findings and recommendations that resulted from a project involving two psychiatrists from a southweast Asian country who were given a specially planned year of training in Hawaii.
Hepatitis C in Austria 1993–2000: reporting bias distort HCV epidemiology in Austria
Authors: R Strauss, G Fülöp, C Pfeifer
Journal: Eurosurveillance (2003)

From 1993 to 2000 in Austria, the notification system registered 2232 cases of hepatitis C whereas 10 607 hospital cases were reported in the hospital discharge register (HDR). These differences can be explained by under–reporting due to lax reporting behaviour and stigma associated with this disease. The distribution of HCV infection varied geographically. The notification data showed the highest incidence rates in Tyrol, while HDR data showed highest hospitalisation rates in Vienna and Lower Austria. This study highlights the urgent need for a clear case definition at the national level and an electronic reporting system.
Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients.
Authors: Tanguy Y. Seiwert, Barbara Burtness, Jared Weiss, Joseph Paul Eder, Jennifer Yearley, Erin Murphy, Michael Nebozhyn, Terri McClanahan, Mark Ayers, Jared K. Lunceford, Ranee Mehra, Karl Heath, Jonathan D. Cheng, Laura Q. Chow
Journal: Journal of Clinical Oncology (2015)

6017 Background: Immunotherapy with anti-PD-1 checkpoint blockade shows encouraging activity in head and neck squamous cell carcinoma (HNSCC). We tested 4 multi-gene expression signatures previously derived in melanoma patients (pts) in PD-L1+HNSCC pts from the KEYNOTE-012 (NCT01848834) study as candidate predictive biomarkers. Methods: 43 of 61 pembrolizumab-treated patients had RNA expression profiling and survival data; 40 were evaluable for objective response. FFPE-extracted RNA was analyzed on the NanoString nCounter system. Four previously established gene signatures (1) "interferon-γ," (2) "TCR signaling," (3) "expanded-immune," and (4) "de novo" were examined as possible predictors for formal hypothesis testing prior to unblinding clinical outcome data. Results: Overall response (OR) rate was 9/40 = 23%. Three signatures showed significant (P < 0.05) association with OR; all 4 signatures showed strong associations (P< 0.005) with PFS. Signature scores and PFS readily segregated into 2 groups (>5 versus <5 months PFS). Using an optimal cutoff for the top-performing interferon-γ signature, positive predictive value (PPV) for response was 40.0%, and negative predictive value (NPV) was 95.0%; AUC = 0.80 [95% CI, 0.61-0.95]. When evaluating the individual signature genes, T-cell–mediated interferon-γ inducible MHC-II expression appeared to be the immune biological connection. Interferon-γ signature correlated strongly with the previously independently discovered inflamed/mesenchymal HNSCC intrinsic subtype (Keck/Seiwert CCR 2015) (R = 0.9). Conclusions: "Inflamed phenotype" signatures are strong predictors of clinical benefit from anti-PD-1 treatment for HNSCC even among a group of patients already considered to be PD-L1+. Clinical trial information: NCT01848834. Nominal 1-sided P valuea Signature OR N = 40 PFS N = 43 IFN-γ (6-gene) 0.005 < 0.001 TCR signaling (13-gene) 0.071 0.002 Expanded-immune (18-gene) 0.015 < 0.001 De novo (33-gene) 0.018 < 0.001 aFrom logistic or Cox regression for overall response and progression-free survival, respectively.
Abstract 18797: Clinical Impact of High on-Prasugrel Platelet Reactivity in an Acute Coronary Syndrome Population
Authors: Stephen A O'Connor, Mathieu Kerneis, Rejane Martin, Jeremie Abtan, Guillaume Cayla, Delphine Brugier, Olivier Barthélémy, Johanne Silvain, Jean-Baptiste Vignalou, Farzin Beygui, Jean-Philippe Collet, Gilles Montalescot
Journal: Circulation (2012)

OBJECTIVE: The aim of this study was to examine the pharmacodynamic and clinical outcome of patients with high on-prasugrel platelet reactivity (HPR). METHODS: Patients with HPR were identified from a group of 388 consecutive patients treated with prasugrel 10mg after PCI for an Acute Coronary Syndrome that had at least 2 different platelet function techniques performed simultaneously. Patients that had one or more technique demonstrating HPR according to the prespecified definitions {VASP≥50% by flow cytometry, P2Y 12 reaction units (PRU) ≥235 using the VerifyNowP2Y 12 assay, residual platelet aggregation (RPA) ≥46.2% using light transmission aggregometry} were included. Data on compliance, therapeutic action, ischemic and bleeding events at one month follow up were collected. RESULTS: Among the 388 patients treated with prasugrel 10 mg, a total of 33 (8.5%) patients with HPR were identified (87.8% male, mean age 60.5±12.5 yrs). The majority of patients had only one of the three techniques performed demonstrating HPR (23/33) (69.7%) and one third of patients (10/33) had at least two different platelet function techniques concordantly demonstrating HPR. Factors associated with HPR were increased BMI (p=0.03), acute stent thrombosis presentation (p&lt;0.0001) and testing in the acute phase (&lt;15 days) (p&lt;0.0001). No therapeutic action was taken in 29/33 cases. A repeat loading dose was administered in 4 cases with HPR defined by at least 2 tests; 3 became responders and 1 patient required 3 loading doses over 3 days to respond. When compared with normal responders (n=355), there was as stepwise increase in ischemic cardiovascular events at 1 month follow up in patients with only 1 test versus patients with at least 2 concordant tests demonstrating HPR (0.8 vs 8.7 vs 30%, p&lt;0.0001) (Figure) CONCLUSIONS: HPR on prasugrel is infrequent and may vary according to the test used. It can be overcome by reloading, but may be associated with an increased ischemic risk at 1 month follow up.
Nutcracker Phenomenon
Authors: K Kimura, T Araki
Journal: New England Journal of Medicine (1996)

Figure 1. Computed tomography in a 52-year-old woman with mild episodic gross hematuria revealed compression of the left renal vein between the superior mesenteric artery (SMA) and the aorta (Ao) before the vein merges into the inferior vena cava (IVC). This compression caused marked dilatation of the distal part of the renal vein (RV). The renal venous congestion caused hematuria, presumably through the rupture of submucosal veins into the renal pelvis. No treatment was given. Entrapment of the renal vein is a known cause of hematuria.
Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.
Authors: Hong Jae Chon, Arthur Cho, Chan Kim, Su Jin Heo, Hyun Cheol Chung, Sung Hoon Noh, Mi Jin Yun, Sun Young Rha
Journal: Journal of Clinical Oncology (2015)

4113 Background: This study aims to investigate the role of preoperative FDG-PET/CT as a prognostic factor in advanced gastric cancer (AGC). Methods: A total of 953 AGC patients who underwent FDG-PET/CT and subsequent curative surgical resection were enrolled from 2003. Afterward, 548 patients with pathologically proven T stage 3 or 4 were visually reassessed and, in patients with positive FDG-PET/CT findings, SUVmax were evaluated as prognostic factors according to histologic subtype for cancer recurrence and death. Results: Of 548 patients, 497 (90.1%) showed positive FDG-cancer uptake. In terms of WHO classification, well or moderately differentiated adenocarcinoma (WMD) demonstrated the highest mean SUVmax, followed by poorly differentiated (PD) and signet ring cell carcinoma (SRC) (WMD: 9.3; PD: 6.4; SRC: 4.8; P < 0.001). Based on Lauren’s classification, intestinal type displayed significantly higher mean SUVmax than diffuse type (Intestinal: 8.5; Diffuse: 5.3; P < 0.001). While mean SUVmax of WMD or intestinal type GC were well correlated with primary tumor size (both P < 0.001), those of SRC or diffuse type GC were not well correlated. TNM stage was not associated with SUVmax regardless of histologic subtype. When patients were divided into two groups (low vs. high SUVmax) based on median SUVmax, High SUVmax group had significantly shorter disease-free survival (DFS; SRC: P = 0.004; Diffuse: P < 0.001) as well as shorter overall survival (OS; SRC: P = 0.007; Diffuse: P < 0.001) than low SUVmax group in SRC or diffuse type GC. However, WMD or intestinal type GC did not demonstrate significant survival difference between low and high SUVmax groups. Multivariate modeling confirmed that high SUVmax patients with diffuse type GC had a significantly increased risk of recurrence and death than those with low SUVmax after adjusting for age, sex, pathologic stage (DFS: HR, 1.73; P < 0.001; OS: HR, 1.84; P< 0.006). Conclusions: FDG uptake of gastric cancer is different according to histologic subtype.FDG PET/CT could provide prognostic information on the prognosis after surgical resection of gastric cancer in SRC or diffuse type GC.
Aspiration: First-Line Erlotinib (E) Until and Beyond Recist Progression (Pd) in Asian Patients (Pts) with Egfr Mutation-Positive (Mut+) Nsclc
Authors: K. Park, M. Ahn, C. Yu, S. Kim, M. Lin, V. Sriuranpong, C. Tsai, J. Lee, J. Kang, P. Perez-Moreno, P. Button, D. Gregory, T.S.K. Mok
Journal: Annals of Oncology (2014)
Current status of laparoscopic liver resection for hepatocellular carcinoma
Authors: Hanisah Guro, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, YoungRok Choi, Mohan Periyasamy
Journal: Clinical and Molecular Hepatology (2016)

Laparoscopic liver resection (LLR) is becoming widely accepted for the treatment of hepatocellular carcinoma (HCC). Laparoscopic left lateral sectionectomy and minor laparoscopic liver resection are now considered standard approaches, especially for tumors located in the anterolateral segments of the liver. Laparoscopic left lateral sectionectomy in adult donors is also gaining acceptance for child liver transplantation in many centers. Major LLRs, including left hepatectomy and right hepatectomy, have been recently attempted. Laparoscopic donor hepatectomy is becoming more popular owing to increasing demand from young living donors who appreciate its minimal invasiveness and excellent cosmetic outcomes. Several centers have performed total laparoscopic donor right hepatectomy in adult-to-adult living donor liver transplantation. Many meta-analyses have shown that LLR is better than open liver resection in terms of short-term outcomes, principally cosmetic outcomes. Although no randomized control trials have compared LLR with open liver resection, the long-term oncologic outcomes were similar for both procedures in recent case-matched studies. Keywords: Laparoscopy; Hepatectomy; Outcome; Prognosis; Recurrence
LG-38MicroRNA PROFILING OF PEDIATRIC LOW-GRADE GLIOMAS (pLGGs)
Authors: Giuseppina Catanzaro, Zein Mersini Besharat, Angela Mastronuzzi, Andrea Carai, Evelina Miele, Agnese Po, Vincenzo Alfano, Marianna Silvano, Manila Antonelli, Felice Giangaspero, Franco Locatelli, Elisabetta Ferretti
Journal: Neuro-Oncology (2016)
LMI-16RESULTS OF MULTIMODAL TREATMENT AND QUALITY OF LIFE IN CHILDREN WITH HIGH RISK CNS TUMOURS IN LVIV REGION: A 10 YEAR EXPERIENCE
Authors: Roman Kizyma, Zoryana Kizyma, Bohdan Kotsay, Iryna Shchurovska, Lesya Dvornyak, Taras Mykytyn, Ivanna Andrejchuk
Journal: Neuro-Oncology (2016)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Authors: Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu
Journal: New England Journal of Medicine (2015)

Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients.In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival.The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001).In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
TSH and prolactin responses to TRH in patients with premenstrual syndrome
Authors: P P Roy-Byrne, D R Rubinow, M C Hoban, G N Grover, D Blank
Journal: American Journal of Psychiatry (1987)

The thyroid-stimulating hormone (TSH) and prolactin responses to thyrotropin-releasing hormone (TRH), administered during the follicular and luteal phases of the menstrual cycle, were examined in 14 women with prospectively confirmed premenstrual syndrome and in nine control subjects. There were no differences in basal or maximum increase in TSH or prolactin values between menstrual cycle phases in patients or in control subjects or between patients and control subjects in either phase. However, there was significantly greater variability in TSH response to TRH among symptomatic patients (seven of 10 patients: three with blunted and four with augmented response) than among control subjects (none of nine patients).
Microbial peptide de-coppers mitochondria: implications for Wilson disease
Authors: Stephen G. Kaler
Journal: Journal of Clinical Investigation (2016)

The severe liver pathology of untreated Wilson disease (WD) is associated with massive copper overload caused by mutations in a liver-specific copper-transporting ATPase, ATP7B. While early, presymptomatic detection and chelation with conventional copper-binding molecules enables effective and life-saving treatment, liver transplantation is the sole option currently available for those with advanced disease. In this issue of the JCI, Lichtmannegger, Leitzinger, and colleagues delineate the therapeutic effect of methanobactin (MB), a potent bacterial copper-binding protein, at three late stages of disease in a WD rat model. Their results suggest that a formal clinical trial of MB in human subjects with severe hepatic pathology caused by WD would be rational.